Targeted sequencing of Parkinson's disease loci genes highlights SYT11, FGF20 and other associations

Genome-wide association studies (GWAS) have identified numerous loci associated with Parkinson's disease. The specific genes and variants that drive the associations within the vast majority of these loci are unknown. We aimed to perform a comprehensive analysis of selected genes to determine the potential role of rare and common genetic variants within these loci. We fully sequenced 32 genes from 25 loci previously associated with Parkinson's disease in 2,657 patients and 3,647 controls from three cohorts. Capture was done using molecular inversion probes targeting the exons, exon-intron boundaries and untranslated regions (UTRs) of the genes of interest, followed by sequencing. Quality control was performed to include only high-quality variants. We examined the role of rare variants (minor allele frequency < 0.01) using optimized sequence Kernel association tests (SKAT-O). The association of common variants was estimated using regression models adjusted for age, sex and ethnicity as required in each cohort, followed by a meta-analysis. After Bonferroni correction, we identified a burden of rare variants in SYT11, FGF20 and GCH1 associated with Parkinson's disease. Nominal associations were identified in 21 additional genes. Previous reports suggested that the SYT11 GWAS association is driven by variants in the nearby GBA gene. However, the association of SYT11 was mainly driven by a rare 3' UTR variant (rs945006601) and was independent of GBA variants (p=5.23E-05 after exclusion of all GBA variant carriers). The association of FGF20 was driven by a rare 5' UTR variant (rs1034608171) located in the promoter region. The previously reported association of GCH1 with Parkinson's Disease is driven by rare nonsynonymous variants, some of which are known to cause dopamine-responsive dystonia. We also identified two LRRK2 variants, p.Arg793Met and p.Gln1353Lys, in ten and eight controls, respectively, but not in patients. We ideniified common variants associated with Parkinson's disease in MAPT, TMEM175, BST1, SNCA and GPNMB which are all in strong linkage disequilibrium (LD) with known GWAS hits in their respective loci. A common coding PM20D1 variant, p.Ile149Val, was nominally associated with reduced risk of Parkinson's disease (OR 0.73, 95% CI 0.60-0.89, p=1.161E-03). This variant is not in LD with the top GWAS hits within this locus and may represent a novel association. These results further demonstrate the importance of fine mapping of GWAS loci, and suggest that SYT11, FGF20, and potentially PM20D1, BST1 and GPNMB should be considered for future studies as possible Parkinson's disease-related genes.

[1]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[2]  A. Singleton,et al.  Genetics of Parkinson's disease: An introspection of its journey towards precision medicine , 2020, Neurobiology of Disease.

[3]  M. Nalls,et al.  Fine‐Mapping of SNCA in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies , 2020, Annals of neurology.

[4]  A. Desautels,et al.  Analysis of common and rare VPS13C variants in late-onset Parkinson disease , 2020, Neurology: Genetics.

[5]  A. Desautels,et al.  The Quebec Parkinson Network: A Researcher-Patient Matching Platform and Multimodal Biorepository , 2019, Journal of Parkinson's disease.

[6]  Sonja W. Scholz,et al.  Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies , 2019, The Lancet Neurology.

[7]  A. Desautels,et al.  Genetic, Structural, and Functional Evidence Link TMEM175 to Synucleinopathies , 2019, Annals of neurology.

[8]  M. Nalls,et al.  Fine-mapping of SNCA in REM sleep behavior disorder and overt synucleinopathies , 2019, bioRxiv.

[9]  A. Desautels,et al.  Analysis of common and rare VPS13C variants in late onset Parkinson disease , 2019 .

[10]  Dawn M. Toolan,et al.  Functionalization of the TMEM175 p.M393T variant as a risk factor for Parkinson disease , 2019, Human molecular genetics.

[11]  E. Alves,et al.  GBA mutations p.N370S and p.L444P are associated with Parkinson's disease in patients from Northern Brazil. , 2019, Arquivos de neuro-psiquiatria.

[12]  W. Chung,et al.  Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson's disease. , 2019, European journal of medical genetics.

[13]  O. Monchi,et al.  Common and rare GCH1 variants are associated with Parkinson's disease , 2019, Neurobiology of Aging.

[14]  C. Paisán-Ruiz,et al.  Identification of a large homozygous VPS13C deletion in a patient with early‐onset Parkinsonism , 2018, Movement disorders : official journal of the Movement Disorder Society.

[15]  A. Brice,et al.  Mutation analysis of Parkinson's disease genes in a Russian data set , 2018, Neurobiology of Aging.

[16]  D. Hernandez,et al.  Coding variation in GBA explains the majority of the SYT11‐GBA Parkinson's disease GWAS locus , 2018, Movement disorders : official journal of the Movement Disorder Society.

[17]  T. Iwatsubo,et al.  LRRK2 and its substrate Rab GTPases are sequentially targeted onto stressed lysosomes and maintain their homeostasis , 2018, Proceedings of the National Academy of Sciences.

[18]  Y. Shimo,et al.  GCH1 mutations in dopa-responsive dystonia and Parkinson’s disease , 2018, Journal of Neurology.

[19]  A. Desautels,et al.  Full sequencing and haplotype analysis of MAPT in Parkinson's disease and rapid eye movement sleep behavior disorder , 2018, Movement disorders : official journal of the Movement Disorder Society.

[20]  Carolyn M. Sue,et al.  Mitochondrial Dysfunction in Parkinson’s Disease: New Mechanistic Insights and Therapeutic Perspectives , 2018, Current Neurology and Neuroscience Reports.

[21]  T. Strom,et al.  Diagnostic exome sequencing in early‐onset Parkinson's disease confirms VPS13C as a rare cause of autosomal‐recessive Parkinson's disease , 2018, Clinical genetics.

[22]  Z. Yue,et al.  Synaptotagmin-11 is a critical mediator of parkin-linked neurotoxicity and Parkinson’s disease-like pathology , 2018, Nature Communications.

[23]  S. Hammes,et al.  Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) and Cancer: A Novel Potential Therapeutic Target , 2017, Steroids.

[24]  M. Nalls,et al.  A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci , 2017, Nature Genetics.

[25]  Xiaomin Wang,et al.  Synaptotagmin‐11 inhibits cytokine secretion and phagocytosis in microglia , 2017, Glia.

[26]  K. Xia,et al.  Rare GCH1 heterozygous variants contributing to Parkinson's disease. , 2017, Brain : a journal of neurology.

[27]  Sunghoon Kim,et al.  The Lysosomal Potassium Channel TMEM175 Adopts a Novel Tetrameric Architecture , 2017, Nature.

[28]  J. Long,et al.  Molecular Mechanisms for the Coupling of Endocytosis to Exocytosis in Neurons , 2017, Front. Mol. Neurosci..

[29]  Jean-François Dartigues,et al.  Discovery and functional prioritization of Parkinson’s disease candidate genes from large-scale whole exome sequencing , 2017, Genome Biology.

[30]  Y. Dauvilliers,et al.  Analysis of DNAJC13 mutations in French-Canadian/French cohort of Parkinson's disease , 2016, Neurobiology of Aging.

[31]  P. Svenningsson,et al.  Strong association between glucocerebrosidase mutations and Parkinson's disease in Sweden , 2016, Neurobiology of Aging.

[32]  Annelot M. Dekker,et al.  NEK1 variants confer susceptibility to amyotrophic lateral sclerosis , 2016, Nature Genetics.

[33]  B. Spiegelman,et al.  The Secreted Enzyme PM20D1 Regulates Lipidated Amino Acid Uncouplers of Mitochondria , 2016, Cell.

[34]  D. Rubinsztein,et al.  The Parkinson's disease-associated genes ATP13A2 and SYT11 regulate autophagy via a common pathway , 2016, Nature Communications.

[35]  R. Young,et al.  Parkinson-associated risk variant in enhancer element produces subtle effect on target gene expression , 2016, Nature.

[36]  W. Chung,et al.  SCARB2 variants and glucocerebrosidase activity in Parkinson’s disease , 2016, npj Parkinson's Disease.

[37]  Simon C. Potter,et al.  Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. , 2016, American journal of human genetics.

[38]  W. Han,et al.  Synaptotagmin‐11 inhibits clathrin‐mediated and bulk endocytosis , 2016, EMBO reports.

[39]  Mitchell J. Machiela,et al.  LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants , 2015, Bioinform..

[40]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[41]  T. Takano,et al.  Injured astrocytes are repaired by Synaptotagmin XI-regulated lysosome exocytosis , 2015, Cell Death and Differentiation.

[42]  G. Deuschl,et al.  MDS clinical diagnostic criteria for Parkinson's disease , 2015, Movement disorders : official journal of the Movement Disorder Society.

[43]  W. Chung,et al.  Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations. , 2015, Brain : a journal of neurology.

[44]  B. Gasnier,et al.  TMEM175 Is an Organelle K+ Channel Regulating Lysosomal Function , 2015, Cell.

[45]  G. Halliday,et al.  Inflammation is genetically implicated in Parkinson’s disease , 2015, Neuroscience.

[46]  L. Buée,et al.  Regulation of human MAPT gene expression , 2015, Molecular Neurodegeneration.

[47]  M. Farrer,et al.  Parkinsonism in GTP cyclohydrolase 1 mutation carriers. , 2015, Brain : a journal of neurology.

[48]  M. Herrero,et al.  Inflammation in Parkinson’s disease: role of glucocorticoids , 2015, Front. Neuroanat..

[49]  K. Morrison,et al.  Novel GCH1 variant in Dopa-responsive dystonia and Parkinson's disease , 2015, Parkinsonism & related disorders.

[50]  Avni Santani,et al.  Actionable exomic incidental findings in 6503 participants: challenges of variant classification , 2015, Genome research.

[51]  F. Tarazi,et al.  Emerging therapies for Parkinson's disease: from bench to bedside. , 2014, Pharmacology & therapeutics.

[52]  M. Waragai,et al.  Role of genomics in translational research for Parkinson's disease. , 2014, Biochemical and biophysical research communications.

[53]  A. Singleton,et al.  Parkinson’s disease in GTP cyclohydrolase 1 mutation carriers , 2014, Brain : a journal of neurology.

[54]  Chuong B. Do,et al.  Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease , 2014, Nature Genetics.

[55]  H. Ohta,et al.  Roles of FGF20 in dopaminergic neurons and Parkinson's disease , 2013, Front. Mol. Neurosci..

[56]  K. Marder,et al.  RAB7L1 Interacts with LRRK2 to Modify Intraneuronal Protein Sorting and Parkinson’s Disease Risk , 2013, Neuron.

[57]  Bradley P. Coe,et al.  Multiplex Targeted Sequencing Identifies Recurrently Mutated Genes in Autism Spectrum Disorders , 2012, Science.

[58]  M. Rieder,et al.  Optimal unified approach for rare-variant association testing with application to small-sample case-control whole-exome sequencing studies. , 2012, American journal of human genetics.

[59]  M. Marazita,et al.  Genome-wide Association Studies , 2012, Journal of dental research.

[60]  A. Mirelman,et al.  Association of sequence alterations in the putative promoter of RAB7L1 with a reduced parkinson disease risk. , 2012, Archives of neurology.

[61]  P. Clayton,et al.  The monoamine neurotransmitter disorders: an expanding range of neurological syndromes , 2011, The Lancet Neurology.

[62]  R. Liu,et al.  Meta-analysis of the relationship between Parkinson disease and melanoma , 2011, Neurology.

[63]  Timothy J. Durham,et al.  "Systematic" , 1966, Comput. J..

[64]  Mohamad Saad,et al.  Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies , 2011, The Lancet.

[65]  Timothy J. Durham,et al.  Systematic analysis of chromatin state dynamics in nine human cell types , 2011, Nature.

[66]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[67]  Yun Li,et al.  METAL: fast and efficient meta-analysis of genomewide association scans , 2010, Bioinform..

[68]  H. Hakonarson,et al.  ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.

[69]  C. Singer,et al.  Increased melanoma risk in Parkinson disease: a prospective clinicopathological study. , 2010, Archives of neurology.

[70]  H. Boezen,et al.  Genome-wide association studies: what do they teach us about asthma and chronic obstructive pulmonary disease? , 2009, Proceedings of the American Thoracic Society.

[71]  Yusuke Nakamura,et al.  Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease , 2009, Nature Genetics.

[72]  Sonja W. Scholz,et al.  Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.

[73]  M. Nalls,et al.  Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. , 2009, The New England journal of medicine.

[74]  K. Ariizumi,et al.  Gpnmb is a melanosome‐associated glycoprotein that contributes to melanocyte/keratinocyte adhesion in a RGD‐dependent fashion , 2009, Experimental dermatology.

[75]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[76]  J. Trojanowski,et al.  FGF20 and Parkinson's disease: No evidence of association or pathogenicity via α‐synuclein expression , 2009, Movement disorders : official journal of the Movement Disorder Society.

[77]  Gaofeng Wang,et al.  Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. , 2008, American journal of human genetics.

[78]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[79]  N. Hattori,et al.  Recessive Parkinson's disease , 2006, Movement disorders : official journal of the Movement Disorder Society.

[80]  A. Singleton,et al.  Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. , 2005, Brain : a journal of neurology.

[81]  Andrew Lees,et al.  Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.

[82]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[83]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[84]  A. Schapira,et al.  Glucocerebrosidase Mutations in Parkinson Disease. , 2017, Journal of Parkinson's disease.